[A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer].

@article{Hatae2005ADE,
  title={[A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer].},
  author={Masayuki Hatae and Takeshi Takahashi and Shoji Kodama and Hiroki Nakayama and Kazuo Kuzuya and Fumitaka Saji and Shoji Kamiura and Yo Watanabe and Ryuichiro Nishimura and Ichiro Kono and Yutaka Ariyosh and Masahiro Fukuoka and Yoshinari Imajo and Kazuo Hasegawa and Kiichiro Noda},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={2005},
  volume={32 4},
  pages={
          473-8
        }
}
Doses of nedaplatin (CDGP) were established for concurrent chemoradiation therapy (CCRT) for cervical cancer, and a collaborative dose escalation study involving 8 hospitals was conducted to investigate the safety and efficacy of this therapy. Radiotherapy was performed according to the standard treatment described in the Regulations of Cervical Carcinoma Treatment. CDGP at 80 mg/m2 as Level 1 or at 90 mg/m2 as Level 2 was administered on Days 1 and 29 of treatment. Dose-limiting toxicity (DLT… CONTINUE READING